Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes BMF-219 是一种新型共价脑膜素抑制剂,旨在再生产生胰岛素的 β 细胞,旨在治愈 1 型糖尿病 美国食品药品管理局已批准启动 COVALENT-112,这是一项针对成人 1 型糖尿病 (T1D) 的 BMF-219 ...
"We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study. Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219. We are rapidly gathering significant proof po...
Ⅱ型糖尿病（diabetes mellitus type Ⅱ，T2DM），旧称非胰岛素依赖型糖尿病（noninsulin-dependent diabetes mellitus，NIDDM）或成人发病型糖尿病（adult-onset diabetes），是一种慢性代谢疾病，多在35～40岁之后发病，占糖尿病患者90%以上。患者特征为高血糖、相对缺乏胰岛素、胰岛素抵抗等。高血糖带来的长期并发症包...
We are continuing to dose escalate and are looking forward to identifying the recommended phase 2 dose [RP2D] within the next several months.” BMF-219 is a covalent inhibitor that suppresses the menin protein, which is involved in oncogenic signaling in genetically defined leukemias and diabetes...
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a potential treatmen...
the clinical and therapeutic potential of our product candidates and development programs, including BMF-219, the potential of BMF-219 as a treatment for various types of cancer and diabetes, our research, development and regulatory plans, including our pursuit of BMF-219 in KRAS solid tumors, an...
https://www.biospace.com/article/releases/biomea-fusion-announces-fda-clearance-of-investigational-new-drug-ind-application-for-bmf-219-in-type-1-diabetes-/ 市监总局发布《保健食品原料 大豆分离蛋白 乳清蛋白备案产品剂型及技术要求》 作者:市场监管总局网站 ...
901-P: COVALENT 112—A Clinical Trial Assessing BMF-219, an Oral Covalent Menin Inhibitor in Type 1 Diabetesdoi:10.2337/db24-901-PBackground and Aims: Inhibition of menin, a scaffold protein, results in beta cell proliferation and enhanced insulin secretion in T1D. BMF-219, an oral ...
[1] Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28. Retrieved March 28, 2023, from https://ww...